Antiarrhythmic drugs and ventricular defibrillation energy requirements

Chinese Medical Journal

Volumn 112, Issue 12, 1999, Pages 1147-1152

  Qi, Xiangqian ^a   Dorian, Paul ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; ACECAINIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIDISOMIDE; BRETYLIUM; CALCIUM ANTAGONIST; CLOFILIUM; ENCAINIDE; FLECAINIDE; IBUTILIDE; LIDOCAINE; MEXILETINE; NIFEKALANT; PROPAFENONE; TEDISAMIL;

DEFIBRILLATION; DEFIBRILLATOR; DOSE RESPONSE; DRUG SAFETY; ENERGY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; MEDICAL LITERATURE; NONHUMAN; REPRODUCIBILITY; REVIEW; SUDDEN DEATH;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DEFIBRILLATORS, IMPLANTABLE; HUMANS; PHENETHYLAMINES; SOTALOL; SULFONAMIDES; VENTRICULAR FIBRILLATION;

EID: 0033458757     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Myerburg RJ, Kessler KM, Castellanon A. Sudden cardiac death: structure, function, and time-dependence of risk. Circulation 1992;85(Suppl I):2-10.
2. Wilber DJ, Garan H, Finklestein D, et al. Out of hospital cardiac arrest: use of electrophysiologic testing in the prediction of long term outcome. N Engl J Med 1988; 318: 19-24.
3. Kuchar DL, Garan H, Ruskin JB. Electrophysiologic evaluation of antiarrhythmic therapy for ventricular tachycarrhythmias. Am J Cardiol 1989; 62: 39H-45H.
4. Kelly PA, Cannon DS, Garan H, et al. The automatic implantable cardioverter defibrillator; efficacy, complications, and survival in patients with malignant ventricular arrhythmias. J Am Coll Cardiol 1988; 11: 1278-1286.
5. Tchou PJ, Kadri N, Anderson J, et al. Automatic implantable cardioverter defibrillator and survival of patients with left ventricular dysfunction. Ann Intern Med 1988; 109: 529-534.
6. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillation in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583.
7. Movsowitz C, Marchlinski FE. Interactions between implantable cardiovertor-defibrillators and class III agents. Am J Cardiol 1998; 82: 41 I-48 I.
8. Woolfolk DI, Chaffee WR, Cohen W, et al. The effect of quinidine on electrical energy required for ventricular defibrillation. Am Heart J 1966; 72: 659-663.
9. Babbls CF, Yim GKW, Whistler SJ, et al. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs. Am Heart J 1979; 98: 345-350.
10. Dorian P, Fain ES, Davy JM, et al. Effect of quinidine and bretylium on defibrillation energy requirements. Am Heart J 1986; 112: 19-25.
11. Echt DS, Gremillion ST, Lee JT, et al. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillation devices. J Cardiovasc Electrophysiol 1994; 5: 752-760.
12. Echt DS, Black JN, Barbey JT, et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. Circulation 1989; 79: 1106-1117.
13. Murakawa Y, Sezaki K, Inoue H, et al. Shock-induced refractory period extension and pharmacologic modulation of defibrillation threshold. J Cardiovasc Pharmacol 1994; 23: 822-825.
14. Ujhelyi MR, O'Rangers EA, Kluger J, et al. Defibrillation energy requirements during moricizine and moricizine-lidocaine therapy. J Cardiovasc Pharmacol 1992; 20: 932-939.
15. Dorian P, Fain ES, Davy JM, et al. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements. J Am Coll Cardiol 1986; 8: 327-332.
16. Jones DL, Klein GJ, Guiraudon GM, et al. Sequential pulse defibrillation in man: effects of lidocaine and verapamil. J Am Coll Cardiol 1989; 13: 216A.
17. Jones DL, Klein GJ, Guiraudon GM, et al. Effects of lidocaine and verapamil on defibrillation in humans. J Electrocardiol 1991; 24: 299-305.
18. Murakawa Y, Inoue H, Kuo TT, et al. Prolongation of intraventricular conduction time associated with fatal impairment of defibrillation efficiency during treatment with class I antiarrhythmic agents. J Cardiovasc Pharmacol 1995; 25: 194-199.
19. Sato S, Tsuji MH, Naito H. Mexiletine has no effect on defibrillation energy requirements in dogs. PACE 1994; 17: 2279-2284.
20. Jung W, Manz M, Pizzulli L, et al. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992; 70: 1023-1027.
21. Marinchak RA, Friehling TD, Kline RA, et al. Effect of antiarrhythmic drugs on defibrillation threshold: Case report of an adverse effect of mexiletine and review of the literature. PACE 1988; 11: 7-12.
22. Hackett AM, Gardiner P, Garthwaite SM. The effect of bidisomide (SC-40230), a new class Ia/Ib antiarrhythmic agent, on defibrillation energy requirements in dogs with healed myocardial infarctions. PACE 1993; 16: 317-326.
23. Natale A, Montenero AS, Bombardieri G, et al. Effects of acute and prolonged administration of propafenone on internal defibrillation in the pig. Am Heart J 1992; 124: 104-108.
24. Montenero AS, Bombardieri G, Barilaro C, et al. Acute effects of propafenone on defibrillation threshold in pigs. Circulation 1989; 80: II-1137.
25. Peters W, Gang ES, Okazaki H, et al. Acute effects of intravenous propafenone on the internal ventricular defibrillation threshold in the anesthetized dog. Am Heart J 1991; 122: 1355-1360.
26. Stevens SK, Haffajee CI, Naccarelli GV, et al. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardiovertor-defibrillators. J Am Coll Cardiol 1996; 28: 418-422.
27. Fain ES, Dorian P, Davy JM, et al. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation 1986; 73: 1334-1341.
28. Hernandez R, Mann DE, Breckinridge S, et al. Effects of flecainide on defibrillation threshold in the anesthetized dog. J Am Coll Cardiol 1989; 14: 777-781.
29. Szabo TS, Jones DL, McQuinn RL, et al. Flecainide acetate does not alter the energy requirements for direct ventricular defibrillation using sequential pulse defibrillation in pigs. J Cardiovasc Pharmacol 1988; 12: 377-383.
30. Rattes MF, Sharma AD, Klein GJ, et al. Adrenergic effects on internal cardiac defibrillation threshold. Am J Physiol 1987; 253: H500-H507.
31. Ruffy R, Schechtman K, Monje E, et al. Adrenergically medicated variations in the energy required to defibrillate the heart: observations in closed-chest, nonanesthetized dogs. Circulation 1986; 73: 374-380.
32. Frame LH. The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs. PACE 1989; 12: 339-346.
33. Guarnieri T, Levine JH, Veltri EP, et al. Success of chronic defibrillation and the role of antiarrhythmic drugs with automatic implantable cardiovertor/defibrillator. Am J Cardiol 1987; 60: 1061-1064.
34. Epstein AE, Ellenbogen KA, Kirk KA, et al. Clinical characteristics and outcome of patients with high defibrillation threshold. A multi-center study. Circulation 1992; 86: 1206-1216.
35. Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J 1987; 114: 8-17.
36. Huang SKS, de Guzman WLT, Chenarides JG, et al. Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardiovertor-defibrillator. Am Heart J 1991; 122: 720-727.
37. Jones DL, Kim YH, Natale A, et al. Bretylium decreases and verapamil increases defibrillation threshold in pigs. PACE 1994; 17: 1380-1390.
38. Tacker WA, Niebauer MJ, Babbs CF, et al. The effect of newer antiarrhythmic drugs on defibrillation threshold. Crit Care Med 1980; 8: 177-180.
39. Kerber RE, Pandian NG, Jensen SR, et al. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: Experimental studies. J Am Coll Cardiol 1986; 7: 397-405.
40. Koo CC, Alten JD, pantridge JF. Lack of effect of bretylium tosylate on electrical ventricular defibrillation in a controlled study. Cardiovasc Res 1984; 18: 762-767.
41. Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol 1993; 72 (Suppl): 72A-79A.
42. Dorian P, Newman D, Sheahan R, et al. D-sotalol decreases defibrillation energy requirements in humans: A novel indication for drug therapy. J Cardiovasc Electrophysiol 1996; 7: 952-961.
43. Wesley RC, Farkhani F, Morgan D, et al. Ibutilide: enhanced defibrillation via plateau sodium current activation. Am J Physiol 1993; 264: H1269-H1274.
44. Gremillion ST, Echt DS, Smith NA, et al. Beneficial effects of intravenous dofetilide in patients undergoing ventricular defibrillation testing. Circulation 1992; 86: I-264.
45. Friedrichs GS, Chi L, Black SC, et al. Antifibrillatory effects of ibutilide in the rabbit isolated heart mediation via ATP-dependent potassium channels. J Pharmacol Exp Ther 1993; 266: 1348-1354.
46. Steinberg MI, Molloy BB. Clofilium - a new antifibrillatory agent that selectively increases cellular refractoriness. Life Sci 1979; 25: 1397-1406.
47. Wang M, Dorian P. DL and D sotalol decreases defibrillation energy requirements. PACE 1989; 12: 1522-1529.
48. Labhasetwar V, Underwood T, Heil RW, et al. Epicardial administration of ibutilide from polyurethane matrices: effects on defibrillation threshold and electrophysiologic parameters. J Cardiovasc Pharmacol 1994; 24: 826-840.
49. Dorian P, Wang M, David I, et al. Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model. Circulation 1991; 83: 614-621.
50. Dorian P, Newman D. Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements. J Cardiovasc Research 1997; 33: 485-494.
51. Murakawa Y, Yamashita T, Ajiki K, et al. Effects of a class III antiarrhythmic drug and bipliasic shocks on the postdefibrillation refractory period of relative refractory myocardium. J Cardiovasc Electrophysiol 1996; 7: 603-611.
52. Qi X, Newman D, Dorian P. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. J Interv Card Electrophysiol 1999; 3: 61-67.
53. Murakawa Y, Yamashiha T, Kanese Y, et al. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol 1997; 29: 688-692.
54. Schräder R, Brooks M, Echt DS. Effects of verapamil and Bay K 8644 on defibrillation energy requirements in dogs. J Cardiovasc Pharmacol 1992; 19: 839-850.
55. Vincent JL, Goldstein J, Dufaye P, et al. Electrophysiological dissociation after ventricular fibrillation: prevention with calcium-entry blockers. J Cardiovasc Pharmacol 1984; 6: 1124-1131.
56. Hite PH, Schräder E, Kieso RA, et al. Effect of calcium channel blockers on hemodynamic response to defibrillation. Am heart J 1989; 117: 569-576.
57. Deeb GM, Hardesty RL, Griffith BP, et al. The effects of cardiovascular drugs on the defibrillation threshold and pathological effects on the heart using an automatic implantable defibrillator. Ann Thorac Surg 1983; 35: 361-366.
58. Lerman BB, Engelstein ED. Metabolic determinants of defibrillation: Role of adenosine. Circulation 1995; 91: 838-844.
59. Wang M, Dorian P, Ogilvie RI. Isoproterenol increases defibrillation energy requirements in dogs. J Cardiovasc Pharmacol 1992; 19: 201-208.
60. Sousa J, Kou W, Calkins H, et al. Effect of epinephrine on the efficacy of the internal cardioverter-defibrillator. Am J Cardiol 1992; 69: 509-512.
61. Wang M, Dorian P. Defibrillation energy requirements differ between anesthetic agents. J Electrophsiol 1989; 3: 86-94.
62. Speck EC, Nemoto EM, Marquez J, et al. Effect of volatile anesthetics on defibrillation threshold in dogs. Anesthesiology 1985; 63: A87.
63. Kim YH, Jones DL, Natale A, et al. Ethanol increases defibrillation threshold in pigs. PACE 1993; 16: 19-25.
64. Qi X, Newman D, Dorian P. Pinacidil decreases coherence during ventricular fibrillation and increases defibrillation energy requirements in dogs. Can J Cardiol 1997; 13(Suppl C): 79.
65. Ruffy R, Monje E, Schechtman K. Facilitation of cardiac defibrillation by amonophylline in the conscious, closed-chest dog. J Electrophysiol 1988; 2: 450-454.
66. Qi X, Newman D, Dorian P. 16-doxyl-stearic acid, a gap junctional blocker, decreases defibrillation thresholds in isolated rabbit hearts. Circulation 1997; 96(Suppl): I-673.